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ABSTRACT
For about four decades, hybridoma technologies have been the “work horse” of monoclonal antibody production. These 
techniques proved to be robust and reliable, albeit laborious. Over the years, several major improvements have been 
introduced into the field, but yet, antibody production still requires many hours of labor and considerable resources. In this 
work, we present a leap forward in the advancement of hybridoma-based monoclonal antibody production, which saves 
labor and time and increases yield, by combining hybridoma technology, fluorescent particles and fluorescence-activated 
cell sorting (FACS). By taking advantage of the hybridomas’ cell-surface associated antibodies, we can differentiate 
between antigen-specific and non-specific cells, based on their ability to bind the particles. The speed and efficiency of 
antibody discovery, and subsequent cell cloning, are of high importance in the field of infectious diseases. Therefore, as 
a model system, we chose the protein LcrV, a major virulence factor of the plague pathogen Yersinia pestis, an important 
re-emerging pathogen and a possible bioterror agent.
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INTRODUCTION
Antibody production is a field of utmost importance, especially in 
the context of detection and treatment of select agents and emerging 
diseases. Despite many developments in the field, hybridoma monoclonal 
antibody production still shows unmatched robustness and reliability 
[1,2]. However, the labor required to produce a large collection of 
antibodies using this method grows exponentially with the number 
of clones. Thus, as antibody characterization methods move into the 
high-throughput era [3], hybridoma antibody production routines still 
remain the rate limiting step in antibody development. In order to 
address these issues and increase the yield of traditional hybridoma 
techniques, we chose to take advantage of fluorescence-activated cell 
sorting (FACS). While traditional hybridoma techniques use “blind” 
distribution of hybridomas into microplates, followed by a process of 
limiting dilution of positive wells, FACS methods sort the contents 
of the fusion and select only hybridomas that bind to a fluorescently 
labeled antigen. Moreover, recent sorter systems allow efficient sorting 
of single cell events, thereby making the cloning step unnecessary [4]. 
In the work presented here, we conjugated fluorescent particles with 
the antigen, and let them bind to hybridomas that present the specific 
antibody on their surface. This way, only “antigen-specific” hybrid-
omas bind the particles and become fluorescently labeled, allowing 
cytometric sorting. The clones are then tested by an enzyme-linked 
immunosorbent assay (ELISA), to characterize the binding properties 
of the antibodies. Only recently, a similar work has been published, 
which used soluble, fluorescent molecules [5]. This approach relies on 
strong antibody display on the cell surface, as the fluorescent signal 
is proportional to the number of labeled antigen molecules that bind 
to it. In the method we present here, the binding of large fluorescent 
particles, rather than soluble proteins, to the hybridomas can produce 
a strong and discrete fluorescent signal even in cases where the surface 
display of antibodies is relatively sparse. Together, the two mutually 
complementary methods demonstrate the great promise that FACS holds 
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for antibody development. We chose to implement our methodology 
on Yersinia (Y.) pestis, the causative agent of plague, both a potential 
bio-terror [6] agent and a re-emerging pathogen [7]. The virulence of 
Y. pestis relies on the type III secretion system (T3SS), which injects 
proteins into host cells. LcrV, which plays a key role in pathogenesis, 
is an important component of the T3SS injection body and a potent 
protective antigen against plague. It has been shown that passive im-
munization by transfer of anti-LcrV antibodies represents a valuable 
post-exposure therapeutic approach, able to protect animals against both 
bubonic and pneumonic plague [8-10]. The localization of LcrV to the 
tip of the T3SS needle [11], suggests that the observed protective effect 
elicited by administration of antibodies may result from prevention of 
the translocation of effectors through the injectisome. Therefore, the 
development of antibodies against LcrV is motivated by two major 
reasons: Firstly, the emergence of antibiotic-resistant Y. pestis strains 
[12] stresses the importance of non-antibiotic treatments, for which 
anti-LcrV antibodies may serve as an attractive option. Secondly, 
anti-LcrV antibodies can be used for the diagnosis of plague infection 
by detecting soluble LcrV in patient blood [13].
MATERIALS AND METHODS
Ethical statement
This study was performed in accordance with the recommendations 
for the Care and Use of Laboratory Animals (National Institutes of 
Health [NIH]). Animal experiments were performed in accordance with 
Israeli law and were approved by the Institutional Ethics Committee 
for animal experiments at the Israel Institute for Biological Research 
(Permit number: IACUC-IIBR M-08-2015).
Preparation of recombinant Y. pestis LcrV
The full-length lcrV coding sequence from the fully virulent Y. pestis 
strain Kimberley53 was cloned into the pGEX expression vector (GE 
Healthcare) and introduced into MC1060 E. coli cells. Recombinant 
LcrV was produced and purified as described previously [14]. Endotoxins 
were removed from the purified protein preparations by the Triton X-114 
phase-separation method [15]. The endotoxin levels that were measured 
by the LAL method were < 1 IEU (international endotoxin units)/50 µg 
of the purified LcrV protein.
Vaccination of mice with rLcrV
For prime vaccination, recombinant LcrV antigen (50 g) was mixed 
with complete Freund’s adjuvant (Sigma, Israel) and for boost vaccina-
tions, a similar dose of the antigen was mixed with incomplete Freund’s 
adjuvant (Sigma, Israel). BALB/c mice (Charles River) received three 
intraperitoneal injections of the adjuvant-antigen mixture (100 L/dose) 
separated three weeks apart. Blood samples were taken prior to each 
vaccination and anti-LcrV IgG titers were determined by ELISA as 
previously described [9]. Three days of the last immunization, mice 
were sacrificed and splenocytes were collected from the spleen in PBS. 
The cells were counted and fused with NS0 cells at a ratio of 1:10 using 
freshly prepared 50% polyethylene glycol MW 1500 (Sigma, Aldrich) 
[16]. After extensively washing the fusion mixture with RPMI 1640, 
the cells were seeded in RPMI supplemented with 10% fetal Bovine 
Serum and HAT [17] (Biological Industries, Israel) in ten 90 mm culture 
dishes for six days.
Cell cultures
Mouse NS0 cells [18] (ECACC No. 85110503) were cultured in 
RPMI 1640 (Biological Industries, Israel) with 10% heat–inactivated 
fetal bovine serum (Biological Industries, Israel).
Preparation of LcrV-conjugated fluorescent particles
Conjugation of LcrV to amine-coated, fluorescent Nile blue particles 
(Spherotech) was performed using EDC and Sulfo-NHS (ThermoFisher) 
by a two-step procedure [19,20]. Briefly, purified LcrV at a concen-
tration of 1 mg/ml was activated with EDC and sulfo NHS (Thermo) 
in MES buffer, pH = 6.0 for 30. After quenching excess EDC with 
β-mercaptoethanol (Sigma), the fluorescent particles were added in 
carbonate buffer, pH = 8.3. The LcrV conjugated particles were then 
washed three times in PBS and stored at 4°C.
Validation of particle binding to hybridomas
106 hybridomas from a reference, anti-LcrV line, were washed twice 
with RPMI and incubated for 30 in a rotator at room temperature with 
either LcrV-or BSA-conjugated particles. Then, the cells were washed 
twice with RPMI and placed on coverslips coated with poly-L-lysine 
(Sigma). The cells were then stained with DAPI (Sigma) and mounted 
with fluoromount on glass slides (Sigma). Imaging was performed using 
a confocal microscope (Zeiss LSM 710).
Sorting
For the sorting, 10% of the fusion plate were washed twice with 
RPMI, mixed with LcrV-coated particles, and incubated for 30' with 
mild shaking. Then, the tube was taken to the FACS (BD FacsAria 
III), for a brief analysis run. The run was used to determine the gating 
parameters for positive clones. Immediately following the analytical 
run, we initiated a sorting run, which sorted the contents of the fusion 
plate into a 96 well plate in a single cell mode, at room temperature. 
In order to obtain an effectively monoclonal sorting, we sorted 10 cells 
per well, which according to our analysis, should produce single clones 
with high probability (see Cloning). In order to verify monoclonality, 
the hybridoma colony formation was followed on a daily basis using 
an inverted microscope (Nikon Eclipse Ts2). The analysis showed the 
development of single viable cells to single colonies per well, which 
later developed to large colonies For extra safety, we performed another 
subcloning step, using limiting dilution.
Hybridoma supernatant processing and biolayer inter-
ferometry
Each hybridoma, positively sorted by the FCM sorter, was grown 
RPMI medium supplemented with 10% NRS, Antibiotic, Thymus ex-
tract (2.5% H6020-sigma). The supernatants from the ELISA-positive 
clones and a non-related clone (negative control) were collected and 
concentrated using an Amicon centrifugal filter device with a MW 
cutoff of 30 K (Merck Millipore). The concentrated supernatants were 
washed once with Octet buffer (PBS buffer, pH 7.4, containing 10 mg/
ml BSA and 0.1% (v/v) Tween 20) to a final volume of 1 ml. Antibody 
binding studies were carried out using the Octet Red system (Forte 
Bio). All steps were performed at 30°C with shaking at 1500 rpm in a 
96-well plate containing 200 µl solution in each well. Octet buffer was 
used throughout this study for antibodies and analytes dilution and for 
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washing the sensors. Streptavidin-coated biosensors were loaded with a 
mouse anti-LcrV biotinylated antibody (5 µg/ml) for 300 s followed by 
a 60 s wash. The sensors were then exposed to LcrV (5mg/ml) for 300 
s, washed again for 60 s and submerged in wells containing the con-
centrated hybridoma supernatant of the different antibodies for another 
300 s followed by another 60 s wash. As a positive control, a polyclonal 
anti-LcrV antibody was used. A supernatant from a non-related mouse 
monoclonal hybridoma was used as a negative control in the assay.
Cloning
Due to the high sensitivity of hybridomas, their survival rates in 
BD FacsAria III’s “single cell” sorting mode were low, and therefore 
not practical for producing a satisfactory number of viable clones in 
reasonable time. In order to cope with this problem, we used a higher 
number of hybridomas per well, as a means to achieve “effective 
monoclonality”. We first determined the survival rates of hybridomas 
following sorting in room temperature, using a “survival test” sort for 
hybridomas. This was done by sorting different numbers of hybridomas 
per well into 96 well plates and analyzing the survival statistics. These 
statistics were used to re-calibrate the sorting conditions, in order to 
obtain single clones with a high probability.
In order to obtain the survival probability for a single cell, we assume 
a simple binomial survival model, in which the probability for a given 
sorted cell to survive, P
survive
, is constant. In such a model, the probability 
for n viable hybridomas (capable of forming a colony) in a well, given 
that N hybridomas were sorted into the well, is given by the binomial 
probability mass function ( ) ( ) * * 1
N nn
N survive survive
N
P n p p
n
− 
= − 
 
.
The probability for observing growth in a well (or non-zero viable 
hybridomas in a well) is: ( ) ( ) ( )0 1 0 1
N
N N surviveP n P n p> = − = = − .
By counting the wells in which hybridomas grew in the calibration 
experiment, we found that when N = 10, 37.5% of the wells were 
positive (36/96 wells), and therefore, ( ) ( )10 0 0.375 1
N
surviveP n p> = = − .
In such a case, 0.023survivep =  and the probability for a well with no 
viable clones, using the binomial model, is ( )10 0 0.79P n = = , and the 
probability for a single clone is ( )10 1 0.19P n = = , strongly decreasing 
with n. Given that a well shows growth (which can easily be determined 
within a few days from the sorting), the probability that it would be 
monoclonal is ( )10
0.19
1| 0.9
1 0.79
P n positive= = =
−
, so in large numbers, 
90% of the wells in which hybridomas grow will be monoclonal.
Figure 1. A simplistic model explaining how, by adjusting the number of cells sorted per well according to experimentally determined survival 
rates, "effectively monoclonal" sorting can be reached. Top: The binomial probability mass function, which approximately describes the number of 
viable cells (capable of growing and forming colonies) in a well. Bottom: When only “growing wells” (the ones in which colonies can be found) are taken 
into account, we can obtain a new probability mass function, defined for 0 < n ≤ 10. In this case, the probability of a “growing well” to be monoclonal is 
~0.9 (or ~90%).
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Data analysis
Analysis and plotting of .fcs files was performed on FlowJo v10. 
Additional statistical analysis and plotting was performed using the 
Scipy programming library for python [21].
RESULTS
Validation of system components
Most of the hybridoma screening methods developed so far, are 
based on the characterization of antibodies secreted by hybridomas 
into the medium. The sorting method, however, relies on the display of 
the antibodies on the outer membrane of the hybridoma, in a way that 
allows the cell, as a whole, to bind the fluorescently-labeled antigen 
and therefore to be sorted by FACS. The conjugation of the antigen 
(LcrV) to the beads was found to be stable for at least three days at 4°C 
in PBS, which was verified using a qualitative immunoassay. Next, we 
used microscope analysis to show that the LcrV-conjugated particles 
bind existing anti-LcrV hybridomas. As can be seen in Figure. 2, the 
hybridoma cells bind the fluorescent particles and not the negative control 
(particles conjugated with BSA). Moreover, under these conditions, the 
cells are monodisperse, i.e., the particles do not form “bridges” between 
cells, which may cause aggregates. This may also be an indication 
of a low number of surface-conjugated LcrV molecules per particle. 
Finally, we analyzed the binding cytometrically. The results (see Fig. 
2 in supplementary information) clearly show binding, and provide 
initial gating parameters for the sorting of freshly-fused hybridomas.
Figure 2. Binding of LcrV-conjugated particles to anti-LcrV hybridoma cells. A. Control particles conjugated with BSA do not bind to the hybridomas. 
B. LcrV-conjugated particles bind to anti-LcrV hybridomas but do not form aggregates.
FACS-aided hybridoma sorting vs. the traditional hy-
bridoma method—an efficiency comparison
Spleens from LcrV-vaccinated mice were harvested for fusion with 
myelomas, after which the resulting cells were divided into two unequal 
groups. Ten percent of the cells resulting from the fusion experiment 
were used in sorting. As a control experiment, we processed the other 
90% of the cells from one of the spleens, using the traditional limiting 
dilution protocol. One week post-fusion, the hybridomas were incubated 
with the Nile blue labeled, LcrV-conjugated particles and then sorted 
by FACS. About 40000 cells were gated using basic light scattering 
properties and analyzed for their fluorescent signal using a 647 nm 
filter set, to detect the Nile blue fluorescence of associated particles. 
The hybridomas that were bound to the Nile blue beads appeared as a 
well-resolved subpopulation (Fig. 3), which was sorted into a 96-well 
plate.
After sorting the hybridomas into 96-well plates, they were grown for 
one week, and the supernatant containing secreted anti-LcrV IgG was 
characterized using ELISA. In order to further validate the method, the 
resulting clones were grown and their medium was tested with ELISA 
against LcrV, and 85% and 93% were found positive in two independent 
experiments. In the control experiment, using the traditional protocol, 
only 7% of the clones were found positive, which is within the known 
range of traditional hybridoma success rate (Table 1 and Fig. 4). Taking 
into account the sample fractions, per spleen, the sorting method should 
have yielded 140–170 positive clones, compared to only 22 positive 
clones using the traditional method (Table 1).
Biolayer interferometry
Biolayer interferometry was used to test the clones from the sorted 
hybridomas. First, soluble anti-LcrV antibodies from six randomly se-
lected cloned were tested for their dissociation rates (see Fig. 5, top). The 
measurements yielded a wide range of rates within the scale of 10-4 s or 
better. In order to demonstrate that chemical conjugation of LcrV to the 
particles can expose different epitopes, antibodies from two different 
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clones were tested for mutual exclusiveness of binding epitopes. As can 
be seen in Fig. 5 (bottom), the method can produce different antibodies 
that are not limited to a certain epitope. Two antibodies, S-7 and S-21 
were purified using a standard IgG protocol [22]. The equilibrium dis-
sociation constants (K
D
) for these antibodies were measured and found 
to be 0.23 and 2.4 nM, respectively. The affinities are comparable to the 
ones we measured for antibodies produced using the traditional method 
(see Table S1, in the Supplementary information).
Figure 3. Sorting freshly-fused hybridomas using the fluorescent signal of LcrV-coated particles. Left: Hybridomas were selected using light scattering 
properties. Right: Hybridomas from the light scattering gate were analyzed according to the intensity in the 647nm channel (Nile blue) and then sorted.
Table 1. The summary statistics for sorting. 
    Sorting method Traditional method
% of total fusion cells 10% 90%
Positive clones/total clones 13/14, 17/20 (93%, 85%) 20/300 (7%)
Calculated clones per entire spleen (estimated by extrapolation) 140–170 22
DISCUSSION
The work presented here shows how combining fluorescently-labeled 
antigens and FACS can dramatically improve hybridoma antibody 
production. This way, one can select specific hybridomas and even (as 
remains to be shown) for more advanced properties (isotype, specificity 
versus universality using multiple antigens, etc.). Our calculations show 
that even in absolute numbers, FACS-based hybridoma workflows can 
yield very large numbers of clones per spleen and therefore does not 
require a high survival rate for the sorted cells. Other hybridoma sorting 
methods use individual, fluorescently labeled, protein molecules, to 
label hybridomas. This way, the fluorescent signal is proportional to the 
level of antibody display on the cell surface, which is not necessarily 
related to the binding properties of the antibody which may lead to the 
loss of valuable clones, due to low or borderline signal. On the other 
hand, by using the fluorescent beads approach, even hybridomas with 
low membrane display of antibodies can be detected and sorted, since 
the binding of even one fluorescent particle to a hybridoma is enough 
to obtain a strong, significant signal. In such scenarios, it is important 
to quickly obtain and analyze large collections of antibodies against 
new variants or strains. Another, indirect, advantage is the reduction of 
animal numbers, as a result of the higher efficiency and yield. The particle 
sorting approach can be further generalized to the use of micron-scale 
particulate antigens (fluorescently labeled bacteria or spores) and to 
the use of magnetic particles, allowing more versatile sorting schemes. 
To summarize, this work demonstrates the great potential that particle 
based, hybridoma sorting holds for the rapid selection of antibodies 
against select agents and emerging pathogens (such as Y. pestis).
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Figure 4. An illustration of the hybridoma sorting method (see Table 1). The sorting experiment was performed 2 times, every time using 10% of the 
spleen content, whereas the traditional hybridoma method used 90% of the spleen content. The efficiency is defined as the fraction of viable hybridomas 
which secrete antibodies with specificity towards the antigen (LcrV).
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Figure 5. Screening of antibodies binding to LcrV. Real-time binding properties of antibodies to LcrV was measured using Octet BLI. Top: Biosensors 
coated with LcrV were used to estimate the Koff for a set of antibodies, from sorted clone media. Following a short wash, each sensor was immersed in a 
well containing concentrated supernatant of a different hybridoma clone (Binding step). This incubation was followed by a wash step, in which unbinding 
occurs, at a rate determined by the antibody’s Koff (Unbinding step). Bottom: Pairwise-mapping analysis for two antibodies against LcrV, chosen from 
the set of antibodies previously analyzed for Koff. Streptavidin-biosensors coated with biotinylated S-7 antibody were submerged in an LcrV-containing 
well and the wavelength interference was recorded (“Antigen Binding”). Following a short wash (“Excess Antigen Dissociation”), one sensor (red) was 
immersed with S-21 antibody while the other (black) was immersed with S-7 antibody (as a control). Both sensors were then washed. The rise in the 
signal for S-21 shows that S-21 can bind to S-7 coated LcrV and therefore the two antibodies do not compete on the same binding site.
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